Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialBrian G. Feagan, Rupert W. Leong, М. Ф. Осипенко et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 235
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flávio Steinwurz et al.|Gastroenterology|2025Cited by 46
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Brian G. Feagan, Anita Afzali et al.|The Lancet|2025Cited by 44
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel diseaseBrian G. Feagan, Chenglong Han, William J. Sandborn et al.|Journal of Patient-Reported Outcomes|2023Cited by 16
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel DiseaseBruce E. Sands, Chenglong Han, Julián Panés et al.|Value in Health|2024Cited by 10